Obstructive Sleep Apnea - Pipeline Insight, 2024

This “Obstructive Sleep Apnea- Pipeline Insight, 2024” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Obstructive Sleep Apnea pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Obstructive Sleep Apnea: Understanding

Obstructive Sleep Apnea: Overview

Obstructive sleep apnea (OSA) is characterized by episodes of breathing cessation or shallow breathing in sleep. These episodes are due to complete or partial collapse of upper airway. Most of the time, the respiratory events are associated with snoring, oxygen desaturations and brief arousal from sleep. Sleep apnea is usually worse during supine and Rapid Eye Movement (REM) sleep. There could be exacerbation of snoring and OSA with alcohol consumption or ingestion of sedative medications. OSA is common and the prevalence is increasing with the increased prevalence of obesity. Daytime sleepiness is among the most common symptoms, but many patients with OSA are asymptomatic. Patients with OSA who are asymptomatic, or whose symptoms are minimally bothersome and pose no apparent risk to driving safety, can be treated with behavioral measures, such as weight loss and exercise. Common obstructive sleep apnea warning signs include: Daytime sleepiness or fatigue, dry mouth or sore throat when person wake up,headaches in the morning,trouble concentrating, forgetfulness, depression, or crankiness, night sweats, restlessness during sleep. Complications of obstructive sleep apnea can include: Sleepiness during the day and trouble concentrating. Adults may have a higher risk of accidents, and children may have a hard time at school. Cardiovascular problems such as heart attack, high blood pressure, unusual heart rhythms, or stroke, eye problems such as glaucoma and dry eye and metabolic disorders like type 2 diabetes. The prevalence of symptomatic OSA or OSA syndrome was only 2% in women versus 4% in men. Obesity is a major risk factor for OSA. OSA is seen in up to 70% of morbidly obese individuals. Other risk factors include advancing age and craniofacial deformities. OSA is also common in smokers, individuals with family history of OSA and in postmenopausal females. Prevalence of OSA increases with coexisting medical conditions like - pregnancy, atrial fibrillation, stroke, congestive heart failure (CHF), Chronic Obstructive Pulmonary Disease (COPD), hypothyroidism, and Polycystic Ovary Syndrome (PCOS).

Obstructive Sleep Apnea- Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Obstructive Sleep Apnea pipeline landscape is provided which includes the disease overview and Obstructive Sleep Apnea treatment guidelines. The assessment part of the report embraces, in depth Obstructive Sleep Apnea commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Obstructive Sleep Apnea collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Obstructive Sleep Apnea R&D. The therapies under development are focused on novel approaches to treat/improve Obstructive Sleep Apnea.

Obstructive Sleep Apnea Emerging Drugs Chapters

This segment of the Obstructive Sleep Apnea report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Obstructive Sleep Apnea Emerging Drugs

Lemborexant : Eisai Lemborexant, is an orexin receptor antagonist that blocks the receptors involved in the regulation of sleep and wakefulness. It is expected to alleviate wakefulness, thereby facilitating faster onset and maintenance of sleep. The drug has recently completed the Phase I trial for the Obstructive SleepApnea.

Sulthiame : Desitin Arzneimittel Gmb HSulthiame is an investigational drug. There have been 4 clinical trials for Sulthiame. The most common disease conditions in clinical trials are Epilepsy, Epilepsy, Rolandic, and Sleep Apnea, Obstructive. Currently the drug is in Phase II for the treatment of Obstructive SleepApnea.

AD 182 : Apnimed AD109 is a first-in-class, oral pharmaceutical combination dosed once-daily at bedtime, designed to treat OSA patients across a broad spectrum of disease severity. AD109 combines a selective norepinephrine reuptake inhibitor (NRI), atomoxetine, with a novel NCE selective antimuscarinic, aroxybutynin. The investigational drug is designed to be safe, effective, and convenient, addressing the key limitations of the current standard of care treatments. AD036 improved multiple objective measures of OSA as well as OSA symptoms, providing proof-of-concept that an oral pharmacologic approach may have clinical benefit in patients withOSA.

TAK-925 : Takeda TAK-925, being studied as an orexin agonist which works selectively on orexin 2 receptors, in sleep-wake disorders characterized by excessive daytime sleepiness (EDS). TAK-925, demonstrated a statistically significant improvement in mean sleep latency measured by the Maintenance of Wakefulness Test (MWT) versus placebo. Currently, the drug is in Phase I stage of development for the treatment ofOSA.

Obstructive Sleep Apnea: Therapeutic Assessment

This segment of the report provides insights about the different Obstructive Sleep Apnea drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Obstructive Sleep Apnea

There are approx. 20+ key companies which are developing the therapies for Obstructive Sleep Apnea. The companies which have their Obstructive Sleep Apnea drug candidates in the most advanced stage, i.e. phase II include, Desitin Arzneimittel GmbH.

Phases

This report covers around 20+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Obstructive Sleep Apnea pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Obstructive Sleep Apnea: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Obstructive Sleep Apnea therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Obstructive Sleep Apnea drugs.

Obstructive Sleep Apnea Report Insights

• Obstructive Sleep Apnea Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Obstructive Sleep Apnea Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Obstructive Sleep Apnea drugs?
• How many Obstructive Sleep Apnea drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Obstructive Sleep Apnea?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Obstructive Sleep Apnea therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Obstructive Sleep Apnea and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Apnimed
• Therapix Biosciences
• Eisai
• Idorsia Pharmaceuticals
• Takeda
• Merck & Co
• Taisho Pharmaceutical Co., Ltd.
• Bayer
• Janssen Pharmaceuticals
• RespireRx Pharmaceuticals
• Cortex Pharmaceuticals
• Michael James Enterprises

Key Products

• AD036
• THX-110
• Lemborexant
• AD182
• AD504
• AD109
• TAK-925
• TS-142
• BAY2586116
• Dronabinol low-dose
• CX 1739

This product will be delivered within 1-3 business days.